MARKET

HCM

HCM

Hutchmed (China) Limited
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.61
+0.03
+0.31%
After Hours: 9.49 -0.12 -1.25% 19:32 05/23 EDT
OPEN
9.64
PREV CLOSE
9.58
HIGH
9.99
LOW
9.15
VOLUME
551.30K
TURNOVER
0
52 WEEK HIGH
43.94
52 WEEK LOW
8.78
MARKET CAP
1.66B
P/E (TTM)
-7.7438
1D
5D
1M
3M
1Y
5Y
20 Stocks Moving in Friday's Pre-Market Session
Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director bought 1,472,126 shares at average price of $0.19 per share.
Benzinga · 4d ago
Appointment of Non–Executive Director
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 and h...
GlobeNewswire · 05/16 11:00
BRIEF-Inmagene Receives FDA IND Clearance For A Third Generation BTK Inhibitor Targeting Immunological Diseases
reuters.com · 05/15 23:02
Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases
Inmagene Biopharmaceuticals ("Inmagene") announces that today the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Ki...
PR Newswire · 05/15 23:00
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, wh...
Benzinga · 05/13 15:55
BRIEF-M&G PLC's Long Position In HUTCHMED Rises To 5.05% - HKEX Filing
reuters.com · 05/13 09:09
Deutsche Bank’s Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced that the presentations from the May 10th and 11th Depositary Receipts Virtual Investor Conference (“dbVIC”) are now available for on-demand viewing. The event featured presentations f...
GlobeNewswire · 05/12 13:54
BRIEF-Capital Group Companies Inc's Long Position In HUTCHMED Rises To 9.18% - HKEX Filing
reuters.com · 05/10 09:43
More
No Data
Learn about the latest financial forecast of HCM. Analyze the recent business situations of Hutchmed (China) Limited through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

36.36%Strong Buy
45.45%Buy
18.18%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HCM stock price target is 33.95 with a high estimate of 50.00 and a low estimate of 17.00.
High50.00
Average33.95
Low17.00
Current 9.01
EPS
Actual
Estimate
-0.20-0.15-0.10-0.05
Q3 2019
Q4 2019
Q1 2020
Institutional Holdings
Institutions: 170
Institutional Holdings: 62.65M
% Owned: 36.23%
Shares Outstanding: 172.91M
TypeInstitutionsShares
Increased
55
3.82M
New
10
254.22K
Decreased
36
5.73M
Sold Out
24
1.07M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.24%
Pharmaceuticals & Medical Research
-0.27%
Key Executives
Chairman/Executive Director
Chi Keung To
President/Managing Director
Marek Kania
Chief Executive Officer/Chief Scientific Officer/Executive Director
Weiguo Su
Chief Financial Officer/Executive Director
Chig Fung Cheng
Chief Operating Officer/Executive Vice President
Karen Atkin
Senior Vice President - Finance
Kin Hung Lee
Senior Vice President
Hong Chen
Senior Vice President
Thomas Held
Senior Vice President
Qingmei Wang
Senior Vice President
Zhenping Wu
General Counsel
Charles Nixon
Secretary/Non-Executive Director
Edith Shih
Non-Executive Director
Dan Eldar
Non-Executive Director
Lefei Sun
Non-Executive Independent Director
Paul Carter
Non-Executive Independent Director
Karen Ferrante
Non-Executive Independent Director
Graeme Jack
Non-Executive Independent Director
Shu Kam Mok
No Data
No Data
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Webull offers kinds of HUTCHMED (China) Ltd (ADR) stock information, including NASDAQ:HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.